GLP-1RAs Preserve Gonadotropins and Sperm Parameters vs TRT

Estimated reading time: 10 minutes

GLP-1RAs may support testosterone while preserving LH and FSH, unlike TRT which suppresses both. Learn what this could mean for semen parameters and family planning.

Key takeaways

GLP-1RAs can raise total testosterone and preserve—or modestly increase—LH and FSH in metabolic hypogonadism, while TRT suppresses both.
Early data suggest GLP-1RAs may improve semen parameters in men with obesity-related hypogonadism; effects are not seen in healthy men without metabolic disease.
Head-to-head signals indicate semaglutide may maintain sperm concentration compared with substantial declines on TRT, with similar short-term symptom and testosterone gains.
TRT labeling (2025) reflects neutral major cardiovascular event risk in appropriately selected men and adds a class-wide blood pressure warning; TRT is still not for age-related low T alone.
Therapy choice should align with diagnosis, metabolic context, fertility goals, and risk tolerance; long-term fertility outcomes with GLP-1RAs remain uncertain.

Why Gonadotropins Matter: LH, FSH, and Sperm Production
TRT: Effective for Symptoms, But Suppresses LH/FSH and Sperm
GLP-1RAs: Metabolic Therapy With Reproductive Upsides
Semaglutide vs TRT: Early Signals From the SEMAT Trial
Who Might Consider GLP-1RAs Over TRT?
Practical Implications if You’re Weighing Options
Risks, Limitations, and What We Still Don’t Know
How Taurus Meds Thinks About GLP-1RAs vs TRT
Conclusion

Why Gonadotropins Matter: LH, FSH, and Sperm Production

LH from the pituitary stimulates testicular Leydig cells to produce testosterone.
FSH supports Sertoli cell function and spermatogenesis.
When LH/FSH are suppressed, intratesticular testosterone falls and sperm production typically declines.

This is why therapies that preserve LH/FSH can be attractive to men who want to support testosterone and symptoms without compromising sperm parameters. It’s also why exogenous testosterone—despite its clear benefits for many men—can reduce fertility potential while on treatment.

TRT: Effective for Symptoms, But Suppresses LH/FSH and Sperm

TRT reliably improves androgen deficiency symptoms in appropriately diagnosed men and raises serum testosterone. However, because exogenous testosterone feeds back to the hypothalamus and pituitary, it suppresses LH and FSH. Over time this typically lowers sperm count and concentration, which may be problematic for men trying to conceive.

What’s new: In February 2025, the FDA implemented class-wide labeling changes to testosterone products. These updates incorporated large outcomes data showing no increase in major cardiovascular events among hypogonadal men who met clinical criteria for TRT. At the same time, the FDA added warnings about increases in blood pressure based on ambulatory monitoring studies. The agency also maintained the limitation of use language advising against TRT for men with age-related low testosterone alone.

What this means in practice:

Cardiovascular risk communication is more nuanced: appropriate patients did not exhibit excess major events, but blood pressure monitoring is emphasized.
The fundamental reproductive endocrinology hasn’t changed: TRT suppresses gonadotropins and can impair semen parameters during use.

For men whose first priority is symptom relief and who are not seeking near-term fertility, TRT remains a well-established option under clinician oversight. For those actively planning fatherhood, alternatives that preserve LH/FSH deserve consideration.

GLP-1RAs: Metabolic Therapy With Reproductive Upsides

GLP-1RAs—such as semaglutide—are primarily prescribed for type 2 diabetes and obesity. In men with metabolic hypogonadism (often obesity- or insulin-resistance–related), they appear to offer a different endocrine profile than TRT:

A 2026 systematic review of 10 studies (639 men) found GLP-1RAs increased total testosterone in men with obesity, type 2 diabetes, or functional/metabolic hypogonadism, while preserving or even modestly increasing LH and FSH. In studies comparing against TRT, the TRT groups showed the expected suppression of LH/FSH.
Importantly, the review reported improvements in semen quality—concentration, motility, morphology—in men with obesity-linked hypogonadism receiving GLP-1RAs. No meaningful semen changes were observed in healthy men without metabolic dysfunction.

These patterns support the idea that GLP-1/gonadotropin dynamics differ from TRT: GLP-1RA LH/FSH signaling tends to be preserved, aligning with fertility-sparing goals. The likely mechanism is indirect—through weight loss, reduced inflammation, improved insulin sensitivity, and possibly direct testicular effects—rather than a classic androgen-replacement mechanism.

A few nuances to keep straight:

Total testosterone tends to rise with GLP-1RAs, but free testosterone responses are inconsistent. As weight decreases, sex hormone–binding globulin (SHBG) may increase, which can blunt free T gains despite higher total T.
Benefits on semen parameters have been documented primarily in men with metabolic dysfunction; they have not been seen in healthy men.

Semaglutide vs TRT: Early Signals From the SEMAT Trial

The ongoing SEMAT program is directly comparing semaglutide with TRT in obese men with type 2 diabetes and hypogonadism over roughly 24 weeks. Early reports summarized in the 2026 systematic review, along with the trial registry, highlight several clinically relevant signals:

Sperm concentration: Semaglutide preserved sperm concentration (+16.7%) while TRT was associated with a marked decline (-60.6%), with a statistically significant between-group difference.
Testosterone and symptoms: Both groups demonstrated improvements in serum testosterone and hypogonadal symptom scores, suggesting comparable short-term symptomatic benefit.
Body composition: Semaglutide produced superior weight and metabolic changes versus TRT in the early data.

What to make of it:

These findings align with the broader GLP-1RA literature suggesting fertility-sparing potential in metabolic hypogonadism.
The data are short-term and, in part, preliminary; full, peer-reviewed results and longer follow-up will be important to confirm durability and real-world generalizability.

Who Might Consider GLP-1RAs Over TRT?

Men whose low testosterone is intertwined with obesity or type 2 diabetes—and who also value fertility preservation—may be candidates for a GLP-1RA–first strategy. This is especially relevant if:

Labs confirm androgen deficiency consistent with metabolic or functional hypogonadism.
There is a near-term intent to conceive, where maintaining LH/FSH and protecting semen parameters is prioritized.
Weight loss, glycemic control, and cardiometabolic risk reduction are central goals.

By contrast, some men may still prefer or need TRT—for example, those with classic primary or secondary hypogonadism where testicular or pituitary dysfunction is not predominantly metabolic, or those who do not have fertility goals during treatment. In such cases, clinicians sometimes consider adjunctive strategies aimed at preserving spermatogenesis, but those require individualized care and are not universally effective.

The bottom line: GLP-1RAs are not a direct substitute for TRT in all forms of hypogonadism and are not approved as fertility treatments. But in the specific context of metabolic hypogonadism, they represent a meaningful, fertility-conscious option to discuss with your clinician.

Practical Implications if You’re Weighing Options

Clarify the cause: Identifying whether low testosterone is primarily metabolic (e.g., associated with obesity, insulin resistance) or due to testicular/pituitary disease influences therapy choice.
Align on goals and timing: If conception is a priority in the near term, preserving LH and FSH is often important. Ask how each option—TRT vs a GLP-1RA—affects gonadotropins and spermatogenesis.
Understand the trade-offs:
- TRT: Predictable symptom relief for many men; suppresses LH/FSH; typically reduces sperm parameters during treatment; label now emphasizes blood pressure monitoring even as major event risk appears neutral in selected patients; still not indicated for age-related low T alone.
- GLP-1RAs: Support weight loss and metabolic health; tend to raise total testosterone and preserve LH/FSH; may improve semen parameters in metabolic hypogonadism; free testosterone responses vary; lean mass can decrease without attention to resistance training and protein intake; long-term fertility outcomes remain uncertain.
Plan monitoring thoughtfully: In fertility-minded care, clinicians may consider tracking LH, FSH, total and free testosterone, SHBG, and semen parameters at baseline and during therapy. Blood pressure monitoring is prudent with any therapy that may affect cardiovascular physiology.

Risks, Limitations, and What We Still Don’t Know

Evidence base: Many GLP-1RA studies are relatively small and short-term (often under 1 year). Bias risk exists in non-randomized designs. High-quality head-to-head trials with standardized semen analysis and longer follow-up are needed.
Population scope: Documented semen benefits are most evident in men with obesity-linked or metabolic hypogonadism. Effects in men without metabolic disease are unclear.
Free testosterone and body composition: SHBG often rises with weight loss, which can limit free T changes despite higher total T. Some men lose lean mass on GLP-1RAs; this underscores the value of a resistance exercise and nutrition plan guided by your care team.
Cardiometabolic safety: TRT labeling now integrates robust cardiovascular outcomes indicating no excess in major events among carefully selected men, but a class-wide warning about blood pressure increases was added. GLP-1RAs have their own side-effect profiles and contraindications; individual risk assessment matters.
Long-term fertility outcomes: Whether GLP-1RAs translate short-term semen improvements into higher natural conception rates over years remains an open question.

How Taurus Meds Thinks About GLP-1RAs vs TRT

At Taurus Meds, our role is to help you choose a path that fits your biology and your goals:

Diagnose precisely: We confirm androgen deficiency with appropriate labs and assess whether the pattern is primarily metabolic.
Map priorities: We discuss symptom relief, metabolic health targets, and family planning timelines to shape the plan.
Present balanced options: We review the pros and cons of TRT and GLP-1RAs—including their effects on LH/FSH, semen parameters, blood pressure, body composition, and practical lifestyle implications.
Monitor and adapt: We track key labs and clinical outcomes, including gonadotropins and semen testing when fertility is a priority, and adjust therapy as your goals evolve.

Conclusion

For men with metabolic hypogonadism who want to improve testosterone while protecting fertility, GLP-1RAs stand out for their preservation of LH and FSH and encouraging signals on semen quality—contrasting sharply with the gonadotropin suppression seen with TRT. Early head-to-head data suggest semaglutide may maintain sperm concentration while delivering symptom and testosterone improvements similar to TRT over the short term.

TRT remains a valuable therapy for appropriately selected men, with updated labeling that clarifies cardiovascular risks and underscores the need to monitor blood pressure. But for those prioritizing conception in the near future—and especially when obesity and insulin resistance are part of the picture—GLP-1RAs merit a serious, evidence-based discussion with your clinician.

The choice is not one-size-fits-all. Your diagnosis, metabolic context, fertility plans, and risk tolerance should guide therapy—grounded in current evidence and revisited as new data emerge.

Disclaimer

This article is for educational purposes only and does not constitute medical advice. Do not start, stop, or change any medication without consulting a qualified healthcare professional.

GLP-1RAs Preserve Gonadotropins and Sperm Parameters vs TRT